Bristol-Myers Squibb Australia Pty Ltd (BMS), have announced that the shortage of abatacept (Orencia) subcutaneous (SC) presentations has been resolved.
Consumers and health professionals are advised that SFI Australasia has initiated a recall for one batch of Ellura capsules due to the presence of ethylene oxide.